Zentalis Pharmaceuticals, Inc.

ZNTL • Biotechnology

$3.99

— 0.00 (0.00%)

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$280.35M

Crecimiento

-100.0%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.18Liquidez saludable · 6.93Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 7 ago 2026, 1:30 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$3.99

Change0.00%

Shares Out70.26M

Market Cap$280.35M

Enterprise Value$139.30M

52W Range1.21 - 6.95

Beta1.93

P/E-1.60

P/B1.95

P/FCF-1.74

EV/EBITDA-0.78

EV/FCF-0.86

Price$3.99

Change0.00%

Shares Out70.26M

Market Cap$280.35M

Enterprise Value$139.30M

52W Range1.21 - 6.95

Beta1.93

P/E-1.60

P/B1.95

P/FCF-1.74

EV/EBITDA-0.78

EV/FCF-0.86

Earnings Yield-62.38%

FCF Yield-57.47%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.18

Current Ratio6.93

Quick Ratio6.93

Revenue 5Y-100.00%

Target$8.33

Target Upside108.77%

Target Median$10.00

Target Range5.00 - 10.00

Volume46.43K

Avg Volume1.17M

EPS Surprise-0.01

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

95/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.18Liquidez saludable · 6.93Rentabilidad débil

Analyst view

Analyst sentiment and price target

ZNTL

Analyst sentiment

Based on 12 analyst votes · 2026-09-05

83/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-07

Bajo

$10.00

Promedio

$10.00

Mediana

$10.00

Alto

$10.00

Resumen de la compañía

IPO: 4/3/2020

Industria: Biotechnology

P/B i: 1.95

Deuda / Patrimonio i: 0.18

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.18

Ratio corriente: 6.93

Ratio rápido: 6.93

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Myers Scott Dunseth

Transacción: 06/16/2026

COMPRA

Cambio

+57,100

Precio

Not reported

Presentación

06/18/2026

Tipo

COMPRA

Kariuki Enoch

Transacción: 06/16/2026

COMPRA

Cambio

+57,100

Precio

Not reported

Presentación

06/18/2026

Tipo

COMPRA

Walker Luke Nathaniel

Transacción: 06/16/2026

COMPRA

Cambio

+57,100

Precio

Not reported

Presentación

06/18/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Myers Scott Dunseth	COMPRA	+57,100	Not reported	06/16/2026	06/18/2026
Kariuki Enoch	COMPRA	+57,100	Not reported	06/16/2026	06/18/2026
Walker Luke Nathaniel	COMPRA	+57,100	Not reported	06/16/2026	06/18/2026
Skvarka Jan	COMPRA	+57,100	Not reported	06/16/2026	06/18/2026
Johnson David Michael	COMPRA	+57,100	Not reported	06/16/2026	06/18/2026
Campbell Shannon	COMPRA	+114,200	Not reported	05/26/2026	05/27/2026
Campbell Shannon	OTRO	0	Not reported	05/22/2026	05/27/2026
Vultaggio Vincent	VENTA	-6,894	$2.42	02/10/2026	02/10/2026
EASTLAND JULIA MARIE	VENTA	-889	$2.39	02/09/2026	02/10/2026
Vultaggio Vincent	VENTA	-3,379	$2.39	02/09/2026	02/10/2026
Bruns Ingmar	VENTA	-335	$2.39	02/09/2026	02/10/2026
EASTLAND JULIA MARIE	VENTA	-7,866	$2.43	02/06/2026	02/10/2026
Vultaggio Vincent	VENTA	-29,951	$2.43	02/06/2026	02/10/2026
Bruns Ingmar	VENTA	-2,962	$2.43	02/06/2026	02/10/2026
Vultaggio Vincent	VENTA	-556	$2.52	02/03/2026	02/04/2026
Vultaggio Vincent	VENTA	-2,540	$2.55	02/02/2026	02/04/2026
EASTLAND JULIA MARIE	COMPRA	+775,000	$2.84	01/08/2026	01/09/2026
Bruns Ingmar	COMPRA	+365,000	$2.84	01/08/2026	01/09/2026
Bucher James B	COMPRA	+100,000	$2.84	01/08/2026	01/09/2026
Vultaggio Vincent	COMPRA	+100,000	$2.84	01/08/2026	01/09/2026

Sobre la compañía

Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Fuente - Link

Competidores

ALXO ARTV DTIL IMMX MGNX PLRX STRO STTK TIL WHWK

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

BlackRock Inc. Invests $18.20 Million in Zentalis Pharmaceuticals, Inc. $ZNTL

BlackRock Inc. acquired a new position in Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 3,753,525 shares of the company's stock, valued at approximately $18,205,000. BlackRock Inc. owned approximately 5.27% of Zentalis Pharmaceuticals as

Defense World

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences:

GlobeNewsWire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on September 1, 2026, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 269,000 shares of the Company's common stock to four (4) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire

Zentalis Pharmaceuticals: Data Due H1 '27 Will Clarify Prospects Of Azenosertib

Zentalis Pharmaceuticals, Inc. earns a cautious Buy rating, driven by azenosertib's potential in Cyclin E1-positive platinum-resistant ovarian cancer (PROC). DENALI and ASPENOVA trials target accelerated and full FDA approval, with pivotal data expected in H1 '27 as a major catalyst. Recent $93m capital raise extends cash runway into 2028, supporting regulatory milestones and mitigating near-term funding risk.

Seeking Alpha

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) (“Zentalis” or the “Company”), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, today announced that it has closed its previously announced underwritten public offering of 26,450,000 shares of its common stock, including 3,450,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares. The shares of common stock were sold to the public at a price of $3.50 per share. The total gross proceeds to the Company from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $92.6 million. All of the shares of common stock sold in the public offering were sold by the Company.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-12	-0.49	-0.5	-0.01
2026-03-26	-0.41	-0.49	-0.08
2025-11-10	-0.49	-0.37	0.12
2025-08-06	-0.56	-0.37	0.19
2025-05-14	-0.67	-0.67	0
2025-03-26	-0.75	-0.66	0.09
2024-11-12	-0.92	-0.56	0.36
2024-08-09	-0.83	-1.24	-0.41
2024-05-07	-0.77	0.14	0.91
2024-02-27	-0.92	-0.83	0.09
2023-11-06	-1.01	-0.79	0.22
2023-08-09	-1.06	-1.85	-0.79